NYSE & NasdaqReal Most Active Sep 24, 2008
Parexel International () fell 1. 23 to 28. (Investors Business Daily)
Canceled Contracts Crush Pharmanet Sep 13, 2008
3%, PAREXEL International (nasdaq: - - ) soared 29. 7%, and Covance (nyse: - - ) shot up 10. (Forbes -- Markets)
Bloomingdale's in talks for store in Prudential Center Sep 9, 2008
Parexel trims '09 earnings projection to 20-21 share Parexel International Corp. a tester of experimental medicines for drug makers, reduced its earnings forecast while raising its revenue projection for the 2009 fiscal year after completing its purchase of computer software-maker ClinPhone PLC. Parexel anticipates earnings per share of 20 to 21 cents in the first quarter ending Sept. 30. That includes the effects of the purchase and a one-time charge of about 2 cents a share from writing off... (Boston Globe)
Survivors angry that pilot tried to land plane in monsoon storm Jul 30, 2008
--description-- parexel international corporation is a. ... for more information about parexel international visit www. (Yahoo News -- Thailand)
Clark Financial Group Announces Commencement of Operations Jul 28, 2008
by Parexel International Corporation, valuations of companies in this space are on the rise. etrials is a prime example of an organization that is undervalued relative to its industry peer group and needs to focus on improving its returns to shareholders; we look forward to assisting in this regard. (Primezone Releases)
Contractors gain as more drug trials are outsourced Jul 22, 2008
The strong outlook has helped lift shares of CROs like Covance and Parexel International despite the turmoil in the stock market this year. In the next three years, analysts expect to see a wave of consolidation as larger CROs absorb more specialized companies to boost their capacity to run trials and test drugs. (International Herald Tribune -- Business)
3 companies get economic assistance from Mass. Jun 26, 2008
Separately, the council approved $915,000 in tax breaks for Parexel International, which helps drug companies manage clinical trials, to open a facility in Billerica this year. Parexel executives said they plan to move 425 employees from existing locations in Waltham and Lowell to Billerica, and hire at least 75 more employees there over the next few years. (Boston Globe)
WuXi's Shortsighted Deal Jun 26, 2008
Higher margins should help it compete for pharma and biotech business against PAREXEL International (Nasdaq: PRXL), PPD (Nasdaq: PPDI), and others. For WuXi, I don't really see the long-term benefit. (MSNBC -- Business)
ExtendMedia, AT&T link for Net content delivery Jun 25, 2008
Parexel guidance exceeds Wall Street projections Waltham pharmaceutical services company Parexel International Corp. issued a forecast for 2009 profit that exceeds current Wall Street expectations. The company expects profit of $1. (Boston Globe)
Mass. Appeals Court rules for Las Vegas developer Jun 14, 2008
Parexel agrees to buy ClinPhone for $177m Parexel International Corp., the tester of experimental medicines for drug makers, will buy computer software maker ClinPhone PLC for $177 million. Holders of ClinPhone will get $2. (Boston Globe)
Senior housing, day care meet with failure at Town Meeting May 17, 2008
Other articles voted on that night included 26 and 27, which sought approval to establish an economic opportunity area for the PAREXEL International and an application by the company for a $10 million expansion, respectively. The new 100,000 square-foot building will employ 500 people, 425 retained and 75 new hires. (Billerica Minuteman, MA)
Phase Forward Introduces Empirica(TM) Trace - Significant New Release of Adverse Event Management Product Mar 3, 2008
Phase Forward s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 260 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,... (BusinessWire)
Nasdaq decides to delist Aspen Technology stock Feb 16, 2008
Parexel buyout proposal for UK company is rejected Parexel International Corp., the provider of clinical research for drug makers, said ClinPhone PLC, a UK provider of software for such studies, rejected a "preliminary" takeover proposal. Parexel is "currently evaluating its options in relation to ClinPhone," the Waltham company said. (Boston Globe)
PAREXEL International Announces 2-For-1 Stock Split Feb 12, 2008
BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: ) announced today that its Board of Directors has approved a 2-for-1 split of its Common Stock, which will be effected by means of a 100% stock dividend ... Josef von Rickenbach, Chairman and CEO stated, "The stock split reflects the confidence that we have for PAREXEL's future growth prospects and opportunities. We believe this action will serve to attract a broader base of investors by making our stock more... (PR Newswire)
In troubled times, firms bring founders back Jan 13, 2008
The winners included local companies such as , a maker of machine-vision systems in Natick, and Parexel International, a Waltham company that coordinates clinical trials of new drugs and devices. Of course, those are the founder-run companies that have already survived the business world's brutal version of Darwinian selection. (Boston Globe)
Platinum Prospects Dec 31, 2007
Parexel International (nasdaq: - - ). Health Care Equipment ce. (Forbes)
The Valley's priciest home sales Dec 26, 2007
Robert Palko is president and chief operating officer of California Clinical Trials Medical Group Inc. and Behavioral and Medical Research LLC in San Diego, which was bought by Parexel International in October 2006 for $65 million. The home was sold by Melvin and Beth Shultz. (AZCentral -- Business)
P/S I Love You Dec 12, 2007
4 for competitor Parexel International () and 3. 6 for business leader Covance (). (SmartMoney)
Phase Forward bernimmt Green Mountain Logic, einen innovativen Anbieter von Software fr das Management von klinischen Phase-I-Studien Oct 31, 2007
ber 250 Organisationen und Regulierungsbehrden zum Einsatz, darunter: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, die US-Arzneimittelaufsichtsbehrde, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec sowie die britische Regulierungsbehrde for Arzneimittel und Gesundheitsprodukte. Weitergehende... (BusinessWire)
Genzyme begins phase 3 trials of Campath for MS Sep 27, 2007
9m buy of Taiwan company Parexel International Corp., a Waltham biopharmaceutical services company, said it completed the acquisition of Taiwan-based Apex International Clinical Research Co. for about $50. 9 million. (Boston Globe)
Stocks to Watch Sep 27, 2007
Parexel International Corp. () said it completed its purchase of Taiwan-based Apex International Clinical Research Co., and restated its forecast to reflect the deal. The biopharmaceutical services company now anticipates consolidated service revenue of $203 to $210 million for the first quarter, and consolidated service revenue of $875 to $910 million for fiscal 2008. (Fox News)
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) Sep 24, 2007
D., Chairman of the Board of CTI. "His leadership experience makes him a great addition to the board." In addition to CTI, Love is currently Chairman of the Board of ImaRx Therapeutics, and he serves on the boards of PAREXEL International, and Molecular Profiling Institute. He previously served on the board of Xilas Medical, Inc. Love has been active with various non-profit organizations as well, serving on the boards of the Cancer Therapy and Research Center (CTRC) in San Antonio, TX, and the... (PR Newswire)
* Business Briefs Aug 29, 2007
The Investment Commission gave its approval yesterday for the buyout of Apex International Clinical Research Co () by Parexel International Holding BV's of the Netherlands. Parexel announced in June it would acquire Apex at NT$82. (Taipei Times, Taiwan -- Business)
Profit rises at American Science & Engineering Aug 7, 2007
Parexel earnings are up 24% on new business Pharmaceutical services company Parexel International Corp. said its fiscal fourth-quarter earnings rose 24 percent, helped by strong new business growth. For the three months ended June 30, net income was $10. (Boston Globe)
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents Jul 25, 2007
Love serves on the Boards of PAREXEL International Inc., ImaRx Therapeutics Inc. and Molecular Profiling Institute. Daniel D. Von Hoff, M.D. is SMi's principal founder and continues to play a vital role in guiding SMi's clinical operations and overall strategy. (PR Newswire)
Potent Little Pills Jun 26, 2007
That puts it at roughly half the size of competitor Parexel International () and a third of the size of Covance () and Pharmaceutical Product Development. It also competes, of course, against the in-house research teams of big customers like Pfizer (). (SmartMoney)
Health Care's Hired Hands Jun 17, 2007
Joe von Rickenbach, chief executive of clinical research firm Parexel International, () was thrilled to ring the opening bell this month at the Nasdaq stock exchange to celebrate his company's 25th anniversary. Senior managers and board members from Parexel attended the ceremony in New York's Times Square on June 6. (Investors Business Daily)
Thursday's Stocks to Watch Jun 7, 2007
Parexel International Corp. () forecast fiscal fourth-quarter net earnings of 35 cents to 37 cents a share and raised its service revenue forecast to a range of $200 million to $203 million. For fiscal 2007, the company expects earnings of $1. (Fox News)
Agency moves to rein in high-risk medical trials in EU Mar 27, 2007
Both the drug's manufacturer and the company that tested it, Parexel International of Waltham, Massachusetts, insisted that they had followed all requirements for the testing of medicines - and a subsequent inquiry in the U.K. generally confirmed that contention. But the inquiry concluded that enhanced procedures might be required for drugs like TGN1412, which overrode an essential regulatory mechanism of the immune system, in the hopes that it could work as a treatment for diseases like... (International Herald Tribune -- Health)
Profit at Affiliated Managers up 26% Jan 25, 2007
Pharmaceutical services company Parexel International Corp. of Waltham said fiscal 2007 second-quarter profit jumped 80 percent on higher service and reimbursement revenue. For the three months ended Dec. 31, 2006, the company earned $9. (Boston Globe)
